USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N43CO120083
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
INTEZYNE TECHNOLOGIES, LLC
3720 SPECTRUM BLVD, STE 104 TAMPA, FL 33612-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)
Agency: HHS
Contract: N43CO120083
Award Amount: $187,222.00
 

Abstract:

This project aims to develop a stabilized epothilone B (Epo B)-loaded micelle for the intravenous delivery of Epo B to solid tumors. The data should demonstrate that Epo B is encapsulated within the micelle with weight-loadings in the range of 1-5% wt/wt Epo B. Crosslinking chemistries will be applied to Epo B-loaded micelles to generate a crosslinked, stabilized, Epo B micelle. It is anticipated that the particle size of micelles will be between 30-100nm. Based on previous studies with iron-crosslinked micelles, pH-dependent release of Epo B is expected in vitro. Crosslinked Epo B micelles are also expected to be more stable in serum than un-crosslinked micelles, in vitro. Administration of crosslinked micelles to cancer cells in vitro should exhibit similar if not identical cytotoxicity as free Epo B. In vivo characterization should result in: (a) determination of the maximum tolerated dose (MTD) of the Epo B micelle in nude mice; (b) the pharmacokinetics of the Epo B micelle compared to free Epo B in nudemice; and (c) the antitumor efficacy of the micelle in two xenograft models. It is anticipated that the Epo B micelle will outperform free drug in terms of having a higher MTD, superior pharmacokinetics, and improved antitumor efficacy compared to free EpoB.

Principal Investigator:

Kevin Sill
813-910-2120
KEVIN.SILL@INTEZYNE.COM

Business Contact:

Kevin Sill
813-910-2120
KEVIN.SILL@INTEZYNE.COM
Small Business Information at Submission:

INTEZYNE TECHNOLOGIES, LLC
INTEZYNE TECHNOLOGIES, INC. 3720 SPECTRUM BLVD, STE 104 TAMPA, FL 33612-

EIN/Tax ID: 201253022
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No